The ISCT Annual Meeting showcases scientific excellence and innovation in the translation of cell and gene therapy. Read the STEM CELLS Portal’s meeting coverage of significant presentations below.
Khalid Shah (Harvard Medical School, USA)
Massimo Dominici (University of Modena and Reggio Emilia, Italy)
How do we move therapies from commercialization to industrialization, with tissue engineering being slightly less mature than cell and gene therapy?
Julie Allickson (Director, Regenerative Medicine Clinical Center, Wake Forest Institute for Regenerative Medicine, Winston-Salem, North Carolina, USA)
Petter Björquist (CEO at VERIGRAFT, Gothenburg, Sweden)
Laura Niklason (Yale University, New Haven, Connecticut, USA and Humacyte Inc., Durham, North Carolina, USA)
Discussion of stem cells and cancer cell-based therapeutics that have been tested in mouse models of cancer in recent years and are quickly moving toward translation.
Dominic Clarke (Global Head of Cell Therapy at HemaCare Corporation, Winston-Salem, North Carolina, USA)
Stuart Curbishley (Head of Business and Project Development, Advanced Therapies Facility, University of Birmingham, UK)
Jean-François Chaubard (Chief Technology Officer at MaSTherCell Global, France)
David Smith (Head, Cell Therapy Manufacturing, Lonza, USA/Healios KK, Japan)
Optimizing a product through process development is a natural step in translating the therapeutic to the clinic. While this is a critical milestone, many of the processes have not been optimized for larger-scale industrialization. This session will evaluate how industry innovators are implementing new processing platforms and strategies to position future products for sustainable industrialization.